|
|
| A Full-Service Solution Partner Disrupting the Outsourcing Paradigm | inSeption Group offers a full-service solution designed to disrupt the current outsourcing paradigm, resurrecting a common-sense approach to rebuild business trust and confidence in a client’s selected vendor. Primarily focused on oncology, hematology, neurodegenerative disorders, and rare/orphan disease indications, with a specialization in cell and gene therapy, inSeption has been a solution for its’ clients who have experienced the progressive degradation of today’s outsourcing options. Contact them. |
|
|
|
|
By Adish Bhatnagar, independent consultant and freelance GxP auditor | The FDA has finalized a guidance on the circumstances that constitute delaying, denying, limiting, or refusing a drug or device inspection. The agency also provides reasons that may cause drugs or devices to be adulterated under the FD&C Act. |
|
|
|
| Optimizing Cell Therapy Supply Chains For Success | e-book | Catalent | When it comes to transporting highly sensitive and valuable materials, such as cell therapies, learn how teams can ensure that unique storage and distribution requirements are met. |
|
|
|
|
|
|
|
.png){kind=logo}
